Evidence map›Paper›PMID 34589618›Full record

ArticleBiochemistry and biophysics reports2021

miR-30a attenuates drug sensitivity to 5-FU by modulating cell proliferation possibly by downregulating cyclin E2 in oral squamous cell carcinoma.

Kenta Kawahara, Masashi Nagata, Ryoji Yoshida, Akiyuki Hirosue, Takuya Tanaka, Yuichiro Matsuoka, Hidetaka Arita, Hikaru Nakashima, Junki Sakata, Keisuke Yamana and 7 more

Open access · goldAbstract read
In one paragraph

Article in Biochemistry and biophysics reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.1field-weighted citation impact, top 61% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 3 institutions in 1 country.

Kenta KawaharaDepartment of Oral & Maxillofacial Surgery, Faculty of Life Sciences, Kumamoto University 1-1-1, Honjo, Chuo-ku, Kumamoto, 860-8556, Japan.
Masashi NagataDepartment of Oral & Maxillofacial Surgery, Faculty of Life Sciences, Kumamoto University 1-1-1, Honjo, Chuo-ku, Kumamoto, 860-8556, Japan.
Ryoji YoshidaDepartment of Oral & Maxillofacial Surgery, Faculty of Life Sciences, Kumamoto University 1-1-1, Honjo, Chuo-ku, Kumamoto, 860-8556, Japan.
Akiyuki HirosueDepartment of Oral & Maxillofacial Surgery, Faculty of Life Sciences, Kumamoto University 1-1-1, Honjo, Chuo-ku, Kumamoto, 860-8556, Japan.
Takuya TanakaDepartment of Oral & Maxillofacial Surgery, Faculty of Life Sciences, Kumamoto University 1-1-1, Honjo, Chuo-ku, Kumamoto, 860-8556, Japan.
Yuichiro MatsuokaDepartment of Oral & Maxillofacial Surgery, Faculty of Life Sciences, Kumamoto University 1-1-1, Honjo, Chuo-ku, Kumamoto, 860-8556, Japan.
Hidetaka AritaDepartment of Oral & Maxillofacial Surgery, Faculty of Life Sciences, Kumamoto University 1-1-1, Honjo, Chuo-ku, Kumamoto, 860-8556, Japan.
Hikaru NakashimaDepartment of Oral & Maxillofacial Surgery, Faculty of Life Sciences, Kumamoto University 1-1-1, Honjo, Chuo-ku, Kumamoto, 860-8556, Japan.
Junki SakataDepartment of Oral & Maxillofacial Surgery, Faculty of Life Sciences, Kumamoto University 1-1-1, Honjo, Chuo-ku, Kumamoto, 860-8556, Japan.
Keisuke YamanaDepartment of Oral & Maxillofacial Surgery, Faculty of Life Sciences, Kumamoto University 1-1-1, Honjo, Chuo-ku, Kumamoto, 860-8556, Japan.
Sho KawaguchiDepartment of Oral & Maxillofacial Surgery, Faculty of Life Sciences, Kumamoto University 1-1-1, Honjo, Chuo-ku, Kumamoto, 860-8556, Japan.
Shunsuke GoharaDepartment of Oral & Maxillofacial Surgery, Faculty of Life Sciences, Kumamoto University 1-1-1, Honjo, Chuo-ku, Kumamoto, 860-8556, Japan.
Yuka NagaoDepartment of Oral & Maxillofacial Surgery, Faculty of Life Sciences, Kumamoto University 1-1-1, Honjo, Chuo-ku, Kumamoto, 860-8556, Japan.
Masatoshi HirayamaDepartment of Oral & Maxillofacial Surgery, Faculty of Life Sciences, Kumamoto University 1-1-1, Honjo, Chuo-ku, Kumamoto, 860-8556, Japan.
Nozomu TakahashiDepartment of Oral & Maxillofacial Surgery, Faculty of Life Sciences, Kumamoto University 1-1-1, Honjo, Chuo-ku, Kumamoto, 860-8556, Japan.
Mayumi HirayamaDepartment of Oral & Maxillofacial Surgery, Faculty of Life Sciences, Kumamoto University 1-1-1, Honjo, Chuo-ku, Kumamoto, 860-8556, Japan.
Hideki NakayamaDepartment of Oral & Maxillofacial Surgery, Faculty of Life Sciences, Kumamoto University 1-1-1, Honjo, Chuo-ku, Kumamoto, 860-8556, Japan.
Kumamoto University · JPHakodate Central General Hospital · JPKyushu Central Hospital of the Mutual Aid Association of Public School Teachers · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We aimed to determine the functional role of the miRNA, which affects drug sensitivity to 5-FU in oral squamous cell carcinoma (OSCC), using two types of 5-FU-resistant and parental OSCC cell lines. MiRNA microarray data showed that miR-30a was significantly upregulated in two resistant cell lines. Therefore, we investigated the effects and molecular mechanism of miR-30a on 5-FU sensitivity. Stable overexpression of miR-30a in parental OSCC cells decreased cell proliferation and attenuated drug sensitivity to 5-FU. Cell cycle analysis indicated that miR-30a overexpression increased the proportion of G1 phase cells and decreased the proportion of S phase cells. MiR-30a knockdown using siRNA reversed the effects of miR-30a overexpression. DNA microarray analysis using miR-30a-overexpressing cell lines and a TargetScan database search showed that

Indexed as

Cyclin E2DMEM, Dulbecco’s Modified Eagle’s MediumDrug resistanceFive-fluorouracilHNSCC, Head and neck squamous cell carcinomamicroRNAmiR-30aOral squamous cell carcinomaOSCC, Oral squamous cell carcinoma

Identifiers

PMID34589618
PMCPMC8461355
OpenAlexW3199719120

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.